17-Acetoxyjolkinolide B irreversibly inhibits IκB kinase and induces apoptosis of tumor cells
Open Access
- 1 June 2008
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 7 (6), 1523-1532
- https://doi.org/10.1158/1535-7163.mct-08-0263
Abstract
Nuclear factor-κB (NF-κB) is critically important for tumor cell survival, growth, angiogenesis, and metastasis. One of the key events in the NF-κB signaling is the activation of inhibitor of NF-κB kinase (IKK) in response to stimuli of various cytokines. We have identified 17-acetoxyjolkinolide B (17-AJB) from a traditional Chinese medicinal herb Euphorbia fischeriana Steud as a novel small-molecule inhibitor of IKK. 17-AJB effectively inhibited tumor necrosis factor-α–induced NF-κB activation and induced apoptosis of tumor cells. 17-AJB had no effect on binding of tumor necrosis factor-α to its receptor or on binding of NF-κB to DNA. It inhibited NF-κB nuclear translocation. Detailed analysis revealed that the direct target of 17-AJB was IKK. 17-AJB kept IKK in its phosphorylated form irreversibly. This irreversible modification of IKK inactivated its kinase activity, leading to its failure to activate NF-κB. The effect of 17-AJB on IKK was specific. It had no effect on other kinases such as p38, p44/42, and JNK. In addition, 17-AJB induced apoptosis in tumor cells. The effects of 17-AJB on apoptosis correlated with inhibition of expression of the NF-κB-regulated genes. Taken together, our data suggest that 17-AJB is a novel type NF-κB pathway inhibitor. Its unique interaction mechanism with IKK may render it a strong apoptosis inducer of tumor cells and a novel type anticancer drug candidate. [Mol Cancer Ther 2008;7(6):1523–32]Keywords
This publication has 34 references indexed in Scilit:
- IκB kinase inhibitors for treating autoimmune and inflammatory disorders: potential and challengesTrends in Pharmacological Sciences, 2007
- Integrating cell-signalling pathways with NF-κB and IKK functionNature Reviews Molecular Cell Biology, 2007
- Inflammation-associated immune suppression in cancer: The roles played by cytokines, chemokines and additional mediatorsSeminars in Cancer Biology, 2006
- Binding of Manumycin A Inhibits IκB Kinase β ActivityPublished by Elsevier BV ,2006
- NF-κB: linking inflammation and immunity to cancer development and progressionNature Reviews Immunology, 2005
- Effects of IKK inhibitor PS1145 on NF-κB function, proliferation, apoptosis and invasion activity in prostate carcinoma cellsOncogene, 2005
- Herbimycin A Abrogates Nuclear Factor-κB Activation by Interacting Preferentially with the IκB Kinase β SubunitMolecular Pharmacology, 2004
- NF-κB: arresting a major culprit in cancerDrug Discovery Today, 2002
- Positive and Negative Regulation of IκB Kinase Activity Through IKKβ Subunit PhosphorylationScience, 1999
- Inhibition of NF-κB by Sodium Salicylate and AspirinScience, 1994